These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 94089)

  • 21. Radioactive iodine therapy in Graves' hyperthyroidism: a prospective study from a tertiary referral centre in north India.
    Sankar R; Sekhri T; Sripathy G; Walia RP; Jain SK
    J Assoc Physicians India; 2005 Jul; 53():603-6. PubMed ID: 16190128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of Graves' hyperthyroidism--prognostic factors for outcome.
    Alfadda A; Malabu UH; El-Desouki MI; Al-Rubeaan KA; Al-Ruhaily AD; Fouda MA; Al-Maatouq MA; Sulimani RA
    Saudi Med J; 2007 Feb; 28(2):225-30. PubMed ID: 17268701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA; Daykin J; Holder R; Sheppard MC
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hyperthyroidism in Graves' disease--antithyroid drug treatment].
    Schumm-Draeger PM
    Z Arztl Fortbild Qualitatssich; 1999 Apr; 93 Suppl 1():41-5. PubMed ID: 10355049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of Basedow-Graves' hyperthyroidism: retrospective analysis after 30 years].
    Pineda G; Arancibia P; Mejía G
    Rev Med Chil; 1998 Aug; 126(8):953-62. PubMed ID: 9830747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
    Howarth D; Epstein M; Lan L; Tan P; Booker J
    Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the long-term efficacy of low dose 131I versus antithyroid drugs in the treatment of hyperthyroidism.
    Chen DY; Jing J; Schneider PF; Chen TH
    Nucl Med Commun; 2009 Feb; 30(2):160-8. PubMed ID: 19194213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in TSH receptor antibody levels (TRAb) as markers of effectiveness of various therapies in Graves-Basedow's disease.
    Bojarska-Szmygin A; Janicki K; Pietura R; Janicka L
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):248-53. PubMed ID: 15314994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence for higher success rates and successful treatment earlier in Graves' disease with higher radioactive iodine doses.
    Sztal-Mazer S; Nakatani VY; Bortolini LG; Boguszewski CL; Graf H; de Carvalho GA
    Thyroid; 2012 Oct; 22(10):991-5. PubMed ID: 22953990
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of diffuse toxic goiter with radioactive iodine in combination with prolonged antithyroid therapy].
    Khramtsova VIa; Potin VV; Shliakhtina LG
    Probl Endokrinol (Mosk); 1977; 23(2):48-51. PubMed ID: 71726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Conservative treatment of diffuse toxic goiter].
    Potin VV
    Sov Med; 1979 Jun; (6):87-91. PubMed ID: 89703
    [No Abstract]   [Full Text] [Related]  

  • 32. Re: simultaneous treatment of toxic diffuse goiter with I-131 and antithyroid drugs: a prospective study.
    Heggi FN
    J Nucl Med; 1981 Apr; 22(4):393-4. PubMed ID: 6162933
    [No Abstract]   [Full Text] [Related]  

  • 33. [Clinical treatment with anti-thyroid drugs or iodine-131 therapy to control the hyperthyroidism of graves disease: a cost-effectiveness analysis].
    Cruz Júnior AF; Takahashi MH; Albino CC
    Arq Bras Endocrinol Metabol; 2006 Dec; 50(6):1096-101. PubMed ID: 17221117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The success rate of radioactive iodine therapy for Graves' disease in iodine-replete area and affecting factors: a single-center study.
    Park H; Kim HI; Park J; Park SY; Kim TH; Chung JH; Choi JY; Kim SW
    Nucl Med Commun; 2020 Mar; 41(3):212-218. PubMed ID: 31895759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The choice of therapy in toxic diffuse goiter.
    Young RL; Dorfman SG
    Arch Intern Med; 1978 Sep; 138(9):1334-5. PubMed ID: 80165
    [No Abstract]   [Full Text] [Related]  

  • 36. [Evaluation of efficiency of the drug treatment of patients with toxic goiter].
    Zelinskiĭ BA; Slobodnianik OA
    Vrach Delo; 1978 Apr; (4):115-8. PubMed ID: 78584
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment of Basedow's disease by long-term administration of synthetic antithyroid drugs associated with small doses of I-131 prescribed without dosimetry. Apropos of 293 cases with a follow-up of 12 years].
    Jaffiol C; Baldet L; Robin M; Papachristou C; Mirouze J; Lapinski H
    Ann Endocrinol (Paris); 1974; 35(1):34-5. PubMed ID: 4138155
    [No Abstract]   [Full Text] [Related]  

  • 38. [The use of succinate-containing preparations in combine therapy of diffuse toxic goiter].
    Iakubovskii SV; Kondratenko GG; Popova II
    Klin Med (Mosk); 2014; 92(8):50-3. PubMed ID: 25790698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Mechanism of the antithyroid effect of reserpine in patients with diffuse toxic goiter].
    Komarovskaia RP; Potin VV; Ugoleva SV
    Probl Endokrinol (Mosk); 1970; 16(4):9-14. PubMed ID: 4102831
    [No Abstract]   [Full Text] [Related]  

  • 40. [Remote results of long-term mercazolyl treatment combined with irradiation of the the hypothalamo-hypophyseal region in patients with diffuse toxic goiter].
    Baranov VG; Nikolaenko NF; Aleksandrovich EI
    Probl Endokrinol (Mosk); 1976; 22(3):37-40. PubMed ID: 59359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.